The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit
Fabris L, Campello E, Cadamuro M, Simioni P. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2023, 1870: 166763. PMID: 37951510, DOI: 10.1016/j.bbadis.2023.166763.Peer-Reviewed Original ResearchMetabolic dysfunction-associated fatty liver diseaseFatty liver diseaseCardiovascular diseaseLiver diseaseInsulin resistanceLiver fibrosisMajor public health problemPublic health problemMAFLD patientsMAFLD progressionCardiometabolic riskMetabolic syndromeOverall mortalityHepatic repairHepatic fibrogenesisHepatic componentGeneral populationTherapeutic targetingHealth problemsTranslational potentialFibrosisDiseaseGenetic factorsRisk profilingStrongest predictorThe tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts
Cadamuro M, Nuozzi G, Simioni P, Fabris L. The tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts. Hepatoma Research 2023, 9: null-null. DOI: 10.20517/2394-5079.2023.94.Peer-Reviewed Original ResearchCancer-associated fibroblastsHepatocellular carcinomaTumor microenvironmentCommon primary liver malignancyFibro-inflammatory conditionPrimary liver malignancyLimited effective treatmentsWorrisome diseaseLiver malignanciesAggressive tumorsEffective treatmentAggressive phenotypeNeoplastic diseaseCell originCirrhotic backgroundEpithelial compartmentTranslational valueSpecific populationsNeoplastic transformationTumorsDiseasePossible ameliorationCell typesRecent findingsFibroblasts